The U.S. Food and Drug Administration (FDA) has cleared Swiss imaging software developer Medimaps Group’s next-generation version of its TBS Osteo software.
The new version enhances bone microarchitecture evaluation, broadens patient eligibility, and improves connectivity within medical facilities, according to the firm. It converts DXA scan data into actionable reports, providing clinicians with a way to assess patients’ osteoporotic fracture risks, Medimaps said.